Literature DB >> 2311171

DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.

L Capolongo1, G Belvedere, M D'Incalci.   

Abstract

The effects of mitoxantrone (Mx) and doxorubicin (Dx) on cytotoxicity and DNA damage as assayed by alkaline elution were studied in two human colon adenocarcinoma cell lines sensitive (LoVo) and resistant (LoVo/Dx) to doxorubicin. Mx was more cytotoxic than Dx to LoVo cells and was partially cross-resistant in LoVo/Dx. In LoVo cells, Mx produced about 5 times more DNA single-strand breaks (DNA-SSB) than Dx, but both drugs caused an equal number of DNA double-strand breaks (DNA-DSB). In LoVo/Dx cells, the number of DNA-DSB was very low for both Dx and Mx, but DNA-SSB were about 20 times higher for Mx. In LoVo cells, the number of DNA-DSB and protein-associated SSB were similar at equitoxic concentrations. For LoVo/Dx, the partial cross-resistance of Mx might be explained by the much higher number of DNA-SSB produced by this drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311171     DOI: 10.1007/bf00686054

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line.

Authors:  B Drewinko; M M Romsdahl; L Y Yang; M J Ahearn; J M Trujillo
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

2.  Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).

Authors:  G Belvedere; A Suarato; C Geroni; F C Giuliani; M D'Incalci
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

3.  Clinical safety and tolerance of mitoxantrone.

Authors:  R J Crossley
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

4.  Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.

Authors:  J W Lown; C C Hanstock; R D Bradley; D G Scraba
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

5.  Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.

Authors:  P A Paciucci; C Keaveney; J Cuttner; J F Holland
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

6.  Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.

Authors:  W T Bellamy; R T Dorr; W S Dalton; D S Alberts
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

7.  Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells.

Authors:  N Maniar; A Krishan; M Israel; T S Samy
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

8.  Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.

Authors:  M Broggini; M Grandi; P Ubezio; C Geroni; F C Giuliani; M D'Incalci
Journal:  Biochem Pharmacol       Date:  1988-12-01       Impact factor: 5.858

9.  Relationship between cytotoxicity and DNA damage in mammalian cells treated with anthracenedione derivatives.

Authors:  S E Locher; R E Meyn
Journal:  Chem Biol Interact       Date:  1983-09-15       Impact factor: 5.192

10.  Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.

Authors:  R Supino; M Mariani; G Capranico; A Colombo; G Parmiani
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more
  4 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Genes required for survival in microgravity revealed by genome-wide yeast deletion collections cultured during spaceflight.

Authors:  Corey Nislow; Anna Y Lee; Patricia L Allen; Guri Giaever; Andrew Smith; Marinella Gebbia; Louis S Stodieck; Jeffrey S Hammond; Holly H Birdsall; Timothy G Hammond
Journal:  Biomed Res Int       Date:  2015-01-13       Impact factor: 3.411

4.  Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair.

Authors:  Ye Zhang; Larry H Rohde; Honglu Wu
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.